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Chronic myeloid leukaemia (CML) progresses from a chronic to a blastic phase, where the 
leukemic cells are proliferative and undifferentiated. The CML is nowadays successfully 
treated with BCR-ABL kinase inhibitors as imatinib and its derivatives. NUMB is an 
evolutionary well-conserved protein initially described as a functional antagonist of NOTCH 
function. NUMB is an endocytic protein associated with receptor internalization, involved in 
multiple cellular functions. It has been reported that MSI2 protein, a NUMB inhibitor, is 
upregulated in CML blast crisis, whereas NUMB itself is downregulated. This suggest that 
NUMB plays a role in the malignant progression of CML. Here we have generated K562 
cells (derived from CML in blast crisis) constitutively expressing a dominant negative form of 
NUMB (dnNUMB). We show that dnNUMB expression confers a high proliferative phenotype 
to the cells. Importantly, dnNUMB triggers a partial resistance to imatinib in these cells, 
antagonizing the apoptosis mediated by the drug. Interestingly, imatinib resistance is not 
linked to p53 status or NOTCH signaling, as K562 lack p53 and imatinib resistance is 
reproduced in the presence of NOTCH inhibitors. Taken together, our data support the 






Chronic myeloid leukemia (CML) is a myeloproliferative neoplasia usually diagnosed 
as an indolent chronic phase characterized by the accumulation of differentiated myeloid 
cells, followed by an accelerated phase where myeloid cell expansion increases, and finally 
progresses into a blast crisis phase where the expanded myeloid cells are more immature 
and aggressive.  The molecular hallmark of all CML is expression of the BCR-ABL tyrosine 
kinase. This fusion oncoprotein is the result of the 9; 22 translocation giving rise to the 
Philadelphia chromosome [1, 2]. BCR-ABL inhibitors as imatinib and other more recently 
introduced inhibitors are the frontline drugs in CML therapy [2, 3]. 
 The available data indicate that CML is a hematopoietic stem cell malignancy where 
BCR-ABL leads to a progressive block of differentiation and increased genetic instability [1, 
4, 5]. Although constitutive expression of BCR-ABL is sufficient to recapitulate the chronic 
phase, the molecular basis underlying the transition from a chronic to an aggressive blast 
crisis phase remains poorly understood.  
 NUMB is an evolutionarily well-conserved protein, initially described as a NOTCH 
inhibitor [6, 7].  In subsequent studies, Numb was shown to be an endocytic protein 
associated with receptor internalization and clathrin dependent endosomal association [8-
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12]. Numb plays a critical role in cell fate determination, displaying a complex pattern of 
functions, controlling asymmetric cell division, cell adhesion and migration, acting on several 
signaling pathways, as preTCR and Hedgehog [13, 14]. Interestingly, there is also evidence 
of a reduction in NUMB expression in some cancers [15-18].  
 The RNA-binding protein MSI2 (Musashi 2) promotes NOTCH signaling by binding to 
the mRNA of Numb, a negative regulator of NOTCH signaling.  Recent reports demonstrated 
that MSI2 is upregulated in blast crisis CML, and correspondingly, NUMB was 
downregulated. Moreover, exogenous expression of NUMB inhibited leukemogenesis [19]. 
Thus, the MSI2–NUMB signaling axis plays a role in the malignant progression of CML and 
the promotion of a more immature aggressive myeloid leukaemia [19, 20]. Additionally, this 
stem cell regulator, MSI2, has been recently described as a prognosis factor in acute 
myeloid leukemia, being involved in the maintenance and engraftment of HSC [21], but 
whether this function is independent of NUMB is under debate [22]. 
To better define the role of NUMB in CML, we engineered a human CML cell line, 
K562, carrying a dominant negative NUMB form (dnNUMB). This is a truncated NUMB 
protein containing the N-terminal phosphotyrosine-binding region (PTB) described as an 
activator of NOTCH signaling [23, 24]. We describe here that NUMB loss of function 




We first set out to generate K562 cells with constitutive expression of dominant-
negative NUMB (dnNUMB). We used as dnNUMB the region of 163 amino acids comprising 
the PTB domain [23] (Fig. 1A).  We added a Myc tag at the N-terminus and the Myc-PTB 
was inserted in the SEWP lentiviral vector  backbone [25] to generate the SdnNUMBWP 
lentiviral vector The SEWP lentiviral vector expressing enhanced green fluorescence protein 
(eGFP) was used as control. The major features of these vectors are depicted in Fig 1B. We 
transduced K562 cells with SdnNUMBWP lentiviral particles to generated the KdnNUMB cell 
line and dnNUMB ectopic expression in the transduced cell lines was analyzed by 
intracellular flow cytometry using an anti-Myc tag antibody. As a control we also transduced 
cells with lentivirus driving GFP expression (KGFP). With increasing volumes of viral 
supernatant we obtained increasing percentages of transduced cells reaching up to 85 % of 
the cells expressing dnNUMB protein (not shown). We selected a pool of transduced cells 
and the expression of dnNUMB was assessed by western blot (Fig. 1C). It is expected that 
the expression of dnNUMB would result in over-activation of NOTCH. Thus, to test whether 
KdnNUMB cells expressed a functional dnNUMB protein, we determined the mRNA levels of 
several NOTCH target genes. For this purpose, total RNA from KdnNUMB and control KGFP 
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cells was extracted and mRNA levels of HES1, E2A, CCND1, CDK2, BCLX (BCL2L1) and 
MYC were analyzed by RT-qPCR. The result showed increased expression of NOTCH 
target genes in KdnNUMB cells (Fig.1D). This indicates that dnNUMB is impairing NOTCH 
signaling in K562 cells through the functional inactivation of NUMB. 
  We next asked whether inhibition of NUMB exerted an effect on K562 cell 
proliferation. The results showed that expression of dnNUMB resulted in an increased 
proliferation rate of KdnNUMB cells, as demonstrated by cell counting (Fig. 2A) and 
thymidine incorporation into DNA (Fig. 2B). In an independent approach, we labeled K562 
cells expressing the dominant negative NUMB as well as control cells with 
bromodeoxyuridine (BrdU) for 24 h. The results showed that K562 cells expressing dnNUMB 
proliferated more than control K562 cells (Fig. 2C). To confirm the above results in lentivirally 
transduced cells we also transfected K562 with a plasmidic dnNUMB expression vector 
(pCEFL-dnNUMB). Several stable dnNUMB-transfectant clones were selected and the 
dnNUMB overexpression confirmed by immunoblot (Fig. 2D). The proliferation of two of 
them was tested by BrdU incorporation and the results showed that these clones proliferated 
faster than the control cells transfected with the empty vector (Fig 2E). Altogether the results 
show that dnNUMB elevated the proliferation rate in K562 cells. The hyperproliferation of 
K562 due to dnNUMB was a striking finding given that parental K562 cells already show a 
high proliferation capacity.   
In view of the association of NUMB-Mushashi with CML progression, we assayed the 
effect of dnNUMB on the response to imatinib, the front-line drug used in this leukemia. In 
parental K562 cells imatinib at concentrations ≥0.5 µM readily induces cell death, as 
previously reported [26, 27]. In contrast, KdnNUMB cells were partially resistant to the 
antiproliferative effect of imatinib, as assessed by viable cell counting (Fig. 3A). Cell cycle 
analysis also demonstrated a higher fraction of KdnNUMB in S phase as compared to 
control cells. This result was reproduced in the presence of imatinib and other BCR-ABL 
inhibitors as dasatinib and nilotinib (Fig. 3B). The KdnNUMB cells also showed a reduced 
imatinib-induced apoptosis, as assessed by the cleavage of poly (ADP-ribose) polymerase	  
(PARP) after immunoblot analysis (Fig. 3C) and the fraction of sub-G1 cells as assessed by 
cell cytometry (Fig. 3D). We asked if this resistance to imatinib was due to the up-regulation 
of BCLX, a NOTCH target gene. BCLX protein expression was determined by immunoblot in 
cells untreated and treated with imatinib. The results show that BCLX levels were similar in 
KGFP and KdnNUMB cells, and that imatinib treatment reduces these levels This reduction 
is even higher in KdnNUMB cells (Fig. 3E). Therefore, the partial resistance to imatinib of 
KdnNUMB cells was not due to increased BCLX levels. As previously reported [28, 29], 




To explore the mechanism for dnNUMB-mediated resistance to imatinib we studied 
the BCR-ABL kinase activity in KdnNUMB cells and in vector-expressing cells. The levels of 
phosphorylated BCR-ABL (which undergoes auto-phosphorylation) and CRKL (a classical 
BCR-ABL kinase substrate) [30] were analyzed by immunoblot. Consistent with their partial 
resistance against imatinib, KdnNUMB cells showed a higher BCR-ABL activity (Fig. 4A). 
Imatinib, however, did not impair the activity of dnNUMB as assessed by the elevated 
expression of different Notch-target genes (Fig. 4b). We conclude that dnNUMB confers a 
partial resistance of BCR-ABL to the growth inhibitory activity of imatinib. It has been 
described that imatinib induces erythroid differentiation in K562 [31] and that NOTCH 
enhances erythroid differentiation in human and mouse hematopoietic cells  [32, 33]. 
Therefore, we tested differentiation of KdnNUMB cells, and we found that mRNA expression 
of erythroid genes, as erythropoietin receptor (EPOR) and several globins, was elevated in 
KdnNUMB cells as compared with control cells (Fig. 4C). The KdnNUMB cells also showed 
increased differentiation when treated with imatinib (Fig. 4C). The same result was found 
when γ-globin levels were determined by immunoblotting (Fig. 4D). The fraction of 
hemoglobinized cells as assessed by the benzidine assay was also higher in KdnNUMB 
cells with respect to control cells (Fig. 4E). K562 can also be differentiated into the 
megakaryocytic lineage by staurosporine [34] but dnNUMB showed no effect on this 
differentiation (not shown). 
Finally, we asked whether dnNUMB effect is a consequence of its activating effect on 
NOTCH or due to other effects, as NUMB is not exclusively involved in NOCTH signaling but 
also mediates the internalization processes for many receptors. To address this question we 
used a γ-secretase inhibitor (DAPT) which specifically blocks NOTCH signaling. As 
expected, the levels of NOTCH Intracellular Domain (NICD), the product of active cleaved 
NOTCH was increased in KdnNUMB cells with respect to parental cells, as shown by 
immunoblot (Fig. 5A). The effect of DAPT on both cell lines was demonstrated by the 
decreased levels of NICD in DAPT-treated cells KGFP and KdnNUMB cells with respect to 
untreated cells (Fig. 5A). We next compared the effects of DAPT on cell proliferation of 
dnNUMB-expressing cells and the control cells. We assayed the dose-dependent effect of 
DAPT (Fig. 5B) and along 72 h of treatment (Fig. 5D). and the results showed that DAPT 
decreased the fast growing phenotype of KdnNUMB cells, but much less than in control 
cells. This result is consistent with the fact that dnNUMB activates the NOTCH pathway, as 
confirmed previously shown (Fig. 1D). The NOTCH inhibitor did not modify the resistance to 
imatinib shown by KdnNUMB cells (Fig. 5C). Moreover, DAPT did not significantly modify the 
expression of CDK2, HES1 and MYC mRNA  (Fig. 6A) or BCLX protein (Fig. 6B) in 
KdnNUMB cells with respect to control cells in the presence of imatinib.  Altogether, these 
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data show that the hyper-proliferative effect of NUMB inhibition and resistance to imatinib in 






Here we describe an increased proliferative rate in the K562 cell line carrying a 
dominant negative form of NUMB. It was previously reported that repression of NUMB could 
be essential for maintenance of blast crisis CML [20]. However, in contrast with that report, 
our results show that the pro-proliferative effect associated with this repression of Numb 
does not depend on p53, as K562 cells are deficient in p53 [35].  
This stimulation in the proliferation could be explained by the up-regulation of several targets 
of NOTCH pathway observed in the K562 cells expressing dnNUMB, which include proteins 
that stimulate cell cycle (e.g., Cdk2, Myc, and E2A). However, it seems to be independent of 
NOTCH-mediated signaling, as the treatment with DAPT, a γ-secretase inhibitor, didn’t have, 
did not exert a relevant effect on the proliferative behavior of KdnNUMB cells. This is 
consistent with reports demonstrating that Notch inhibition does not impair K562 growth [36] 
and with the phenotype of dnNUMB transgenic mice, which, unexpectedly, is different from 
that of activated Notch transgenic mice [37, 38]. Our results suggest that pathways other 
than NUMB-NOTCH are being inhibited in KdnNUMB. It is conceivable that NUMB acts as 
endocytic adaptor for internalization of receptors required for CML cells proliferation, and 
dnNUMB will enhance or maintain the signaling form these receptors 
Imatinib is an inhibitor of BCR-ABL, nowadays the front-line drug for CML, together 
with other related molecules, as dasatinib or nilotinib. One of the most important caveats for 
the treatment of CML is the acquired resistance to imatinib observed in a substantial 
proportion of patients due to prolonged drug exposure, which makes them refractory to this 
treatment and causes patient relapse [39]. We describe that dnNUMB-K562 cells show 
partial resistance to the cells death induced by imatinib and related molecules (dasatinib or 
nilotinib). This resistance is consistent with the unabated activity of BCR-ABL kinase of 
KdnNUMB cells in the presence of imatinib as assessed by CRKL phosphorylation. In 
agreement with this result, it has been recently shown in primary CML cells that NOTCH  
signaling leads to BCR-ABL hyperactivation [40]. It has also been reported that imatinib 
induces erythroid differentiation in K562 cells [31] and NOTCH activity stimulates erythroid 
differentiation in hematopoietic cells [32, 33]. We found that dnNUMB expression not only 




Further work will be required to unveil the mechanism for this interaction the 
interaction between NUMB and BCR-ABL. In summary, our results suggest that low NUMB 
levels or activity contribute to proliferation of CML cells through mechanisms independent of 
NOTCH and p53. This finding support the hypothesis that activation or stabilization of NUMB 




MATERIALS AND METHODS 
Cell Culture: All K56-derived cell lines were culturing in non-tissue culture plates using 
RPMI 1640 medium supplemented with 10% fetal calf serum and gentamycin (60 µg/ml) at 
37ºC under normoxia conditions. HeLa cells were grown in DMEM with 10% fetal calf serum 
and gentamycin (60 µg/ml). Kbcl2 and KbclX cell lines were previously described [28, 29]. 
Cells were passaged every 3 days. Cell proliferation was assayed with a Nucleocounter 
(Chemometec). When indicated, cells were treated with imatinib, dasatinib or nilotinib (from 
LC Laboratories) or DATP (Sigma-Aldrich). 
Cell cycle and erythroid differentiation analysis. Cell cycle distributions were assayed by 
ethanol fixation overnight and propidium iodide (PI) staining of  DNA followed by 
fluorescence-activated cell sorting using Guava EasyCyte Flow Cytometer (Guava 
Technologies), following the manufacture’s instructions. Viable cell counts were determined 
with the same cytometer using the ViaCount assay kit. The fraction of hemoglobin-producing 
cells was scored by the benzidine assay essentially as described [41] 
 
Immunoblot: Nuclear and cytoplasmic extracts were obtained using lysis buffer (1% NP40, 
0.2% SDS, 50 mM Tris-HCl pH 7.5, 100 mM NaCl, 1 mM EDTA, 10% glycerol, 10 mM NaF 
and protease inhibitors) for 20 minutes at 4°C. Lysates were cleared by centrifugation after 4 
pulses ON/OFF of 30sc in the Bioruptor. 50 µg of lysates were subjected to immunoblot as 
described [42]. The antibodies used were anti-MYC tag (mouse monoclonal from Santa Cruz 
Biotech, 9E10), anti-PARP (rabbit polyclonal, from Santa Cruz Biotech, H-250), anti-cleaved 
NOTCH1 (NICD, Val1744) (rabbit polyclonal from Cell Signalling), anti-BCLX (rabbit 
monoclonal from  Cell Signalling), anti-BCL2 (mouse monoclonal from BD Transduction 
Laboratories), anti γ-globin (rabbit polyclonal from Santa Cruz Biotech), anti anti-β-actin 
(goat polyclonal from Sigma, I-19) and anti-α-tubulin (mouse monoclonal from Sigma, 
T6074). All antibodies were from Santa Cruz Biotech and were diluted 1:1000.The blots 
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were developed with secondary antibodies conjugated to IRDye680 and IRDye800 (Li-Cor 
Biosciences) and visualized in an Odyssey scanner. 
RNA extraction and expression analysis Total RNA was isolated using Trizol or RNeasy 
kit (Qiagen). For reverse transcription and polymerase chain reaction (RT-PCR), first-strand 
cDNA was synthesized from 1 µg of total RNA using SuperScriptTM II RNase reverse 
transcriptase (Invitrogen) and random primers. Quantitative RT-PCR was performed with a 
SYBR Green PCR kit (BioRad). The expression levels were normalized to the expression of 
human actin mRNA r human ribosomal protein S14 (RPS14). The primers used in the PCR 
reactions are described in Table 1. 
3H-Thymidine incorporation: 5x104 cells per well were cultured during 72h in a 96 well 
plate. Cultures were pulsed with 0.3uCi of 3H-thymidine (3H-TdR) for the final 15 hours of 
culture, harvested, and counted  
BrdU labeling. BrdU labeling was performed by incubating K562 cells at 37°C in medium 
containing 100 µg/ml BrdU (Sigma). After 24 hours, cells were collected, washed with PBS 
and incubated with Lysis Solution FACs (BD Bioescience). Then, they were fixed with 1% 
paraformaldehyde (Panreac) and NP-40 (Sigma) for 30 minutes at 4ºC. Cells were 
incubated with Dnase I (Sigma) for 30 minutes and stained with BrdU-FITC for 45 minutes, 
followed by flow cytometry analysis. 
Lentiviral vectors. The HIV packaging (pCMVDR8.91) and VSV-G (pMD.G) plasmids have 
been described elsewhere [43, 44]. The HIV packaging pCMVDR8.91 encodes gag, pol, tat 
and rev genes. The pMD.G plasmid encodes the Vesicular Stomatitis Virus (VSV) G protein 
(VSVg). The lentiviral vector plasmid SEWP (HRSIN-CSGW) [25] encodes the emerald 
green fluorescent protein (eGFP) under the control of the spleen focus forming virus (SFFV) 
promoter and contains the Woodchuck post-regulatory element (WPRE). The lentiviral 
vector SPTBNWP was generated by replacing the eGFP cDNA in the SE vector for a 519 bp 
fragment containing the PTB domain of numb gene with a Myc tag. To do this we generated 
a PCR fragment from the p-EF-Numb plasmid using the following primers:  Forward: 
5’CCGGATCCCACCATGGAACAAAAACTTATTTCTGAAGAAGATCTGAACAAACTACGGC
AAAGCTTCAGG-3’ and Reverse: 5’-CGCGCGGCCGCCTACTACTACTTCTCCCGC 
TTCTGTTTACGCTC-3’ and cloned it into pGEM-T easy vector (Promega Corp.). The 519 
bp fragment containing the PTB domain of numb and the myc tag was excised from pGEM-T 
by BamHI-NotI digestion and inserted into the lentiviral vector backbone. For, vector 
production, 293T cells were transfected with the three plasmids described above 
(pCMVDR8.91, pMD.G and SEWP or SPTBNWP) using Lipofectamine 2000 (GibcoBRL) as 
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previously described [45]. Two days after transfection, supernatants containing vector 
particles were harvested and filtered through 0.22um and frozen at -80oC until use. Lentiviral 
particles were concentrated by ultrafiltration at 2000×g and 4°C, using 100 kDa centrifugal 
filter devices (Amicon Ultra-15, Millipore, Billerica, MA) 
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Figure 1 Construction of KdnNUMB. (A) Schematic drawing of the NUMB protein and the 
region used as dnNUMB in this study. The Phosphotyrosine-Binding domain (PTB) and 
Prolin Rich Region (PRR) domains are as described [23].  (B) Schematic drawing of the 
lentiviral constructs used in this work. LTR, long terminal repeat; Ψ, retroviral packaging 
signal; SFFV, spleen forming focus virus LTR promoter; WPRE, woodchuck hepatitis virus 
posttranscriptional regulatory element. (C) Immunoblot showing dnNUMB protein expression 
in K562 transduced with dnNUMB lentivirus, using an anti-Myc tag antibody. Actin levels 
were determined as a protein loading control of the samples. (D) mRNA levels of the 
indicated NOTCH target genes, determined by RT-qPCR in KdnNUMB and KGFP cells. The 
data are mean values from two independent RNA preparations. Error bars are SEM. 
Figure 2 Proliferation rate of KdnNUMB Higher proliferation ratio of KdnNUMB vs. control 
cell line KGFP analyzed by (A) Viable cells counting at different times in culture (mean 
values of three independent experiments, error bars are SEM); (B) 3H-Thymidine 
incorporation after 72h in culture (mean values of two experiments with SEM) and (C) 
Incorporation of BrdU for 24 hours. (D) dnNUMB overexpression tested by Immunoblot in 
several dnNUMB-transfected stable clones carrying PCEFL KdnNUMB. (E) BrdU uptake 
after 24 hours of two different clones, measured by intracellular flow cytometry. K562 cells in 
the absence of BrdU (thin solid line), control K562 cells (thick solid line) or K562-dnNb cells 
(broken line). Data are representative of three independent experiments. 
Figure 3. KdnNUMB resistance to Imatinib. (A) Viable cell counting along 72 h of culture 
after addition of 0.5 µM of Imatinib, showing a partial resistance to the antiproliferative effect 
of the drug. (B) Fraction of cells in S-phase of the cell cycle in KGFP and KdnNUMB treated 
with 50 nM dasatinib, 50 nM nilotinib or with 0.5 µM Imatinib respectively for 24 hours. (C) 
Reduced imatinib-induced apoptosis assessed by Immunoblot of the cleavage of PARP 24 
hours after addition of 0.5 µM imatinib. The arrows mark the position of uncleaved (116 kDa) 
and cleaved PARP (89 kDa). (D) DNA content of KGFP and KdnNUMB cells treated with 1 
µM imatinib for 24 h. Cells were stained with propidium iodide and analyzed by flow 
cytometry. (E) Expression of BCLX and BCL2 analyzed by immunoblot in KGFP cells and 
KdnNUMB. HeLa and KBcl2 cells were included as controls for the expression of BCLX and 
BCL2, respectively. Cells were treated for 24 h with 1 µM imatinib. Actin levels were 
determined as a control for protein loading. The lane “M” contains the molecular weight 
markers. 
Figure 4. Activity of KdnNUMB over BCR ABL and NOTCH pathway. (A) Immunoblot 
showing higher levels of phospho-BCR-ABL and his phosphorylated substrate P-CRKL in 
KdnNUMB cells. Actin levels were determined as a protein loading control of the samples. 
(B) mRNA levels assessed by real time PCR of different NOTCH target genes 48 hours after 
addition of 0.5 µM imatinib.. Mean data of two experiments with SEM bar errors. (C) mRNA 
expression of indicated erythroid specific genes in KGFP and KdnNUMB cells untreated or 
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treated for 24 h with 1 µM imatinib. mRNA was determined by RT-qPCR. Data are relative to 
the basal expression in KFGP cells. β-globin mRNA expression is shown in a different scale. 
(D) Immunoblot showing the expression of γ-globin protein in KGFP and KdnNUMB cells. 
Actin levels were determined as a protein loading control. (E) Fraction of hemoglobin-
producing cells in KGFP and KdnNUMB cells treated for 36 h with 0,5 µM imatinib. The 
hemoglobinized cells were scored by the benzidine cytochemical test. 
Figure 5. dnNUMB-mediated resistance to imatinib does not depend on Notch 
signaling. (A) Notch cleavage inhibition by DATP en K562 cells. Cells were treated with 5 
µM DAPT and, when indicated, with 1 µM imatinib for 24 h. Cell lysates were prepared and 
the protein levels of cleaved intracellular Notch an alpha-tubulin were assessed by western 
blot.  NICD, NOTCH Intracellular Domain. (B) Cell proliferation of KGFP and KdnNUMB cells 
treated for 48 h with 5 µM and 10 µM DAPT, assessed by cell counting. Data are mean 
values of two independent experiments, error bars are S.E.M.  (C) Cell proliferation of KGFP 
and KdnNUMB treated with 10 µM DAPT and 1 µM imatinib as indicated. The cell countings 
were normalized to the proliferation of untreated cells.  
Figure 6. Expression of Notch target genes in KGFP and KdnNUMB. (A) Cells were 
treated for 24 h with 1 µM imatinib and/or 10 µM DAPT as indicated. The mRNA expression 
of the indicated genes was determined by RT-qPCR and normalized against the expression 
of β-actin mRNA. Data are mean values of two independent experiments. (B) Immunoblot 
showing BCLX levels in KGFP and KdnNUMB treated for 24 h with 1 µM imatinib and 10 µM 




Table 1. List of primer used in the RT-qPCR assays in this work. All primers are form human 
genes and have a TM of 57ºC 
Gene Forward primer Reverse primer 
β-Actin AAAATCTGGCACCACACCTTC TAGCACAGCCTGGATAGCAA 
BCL2L1/BCLXL ACATCCCAGCTCCACATCAC AAGAGTGAGCCCAGCAGAAC 
CCND1	   CCCTCGGTGTCCTACTTCAA	   AGGAAGCGGTCCAGGTAGTT	  
CDK2 GGAGAACTTCCAAAAGGTGGA GAGATCTCTCGGATGGCAGT 
EPOR CTGGTCGGAGCCTGTGTC GAGCACGGTCAGCAGCAC 
β-globin TTGCCACACTGAGTGAGCTG GCCACCACTTTCTGATAGGC 
γ-globin GCTCTGAATCATGGGCAGTG TGAACTGCACTGTGACAAGC 
HES1 CGGACATTCTGGAAATGACA GTGCGCACCTCGGTATTAAC 
MYC AAGACTCCAGCGCCTTCTCT GTTTTCCAACTCCGGGATCT 
RPS14 TCACCGCCCTACACATCAAACT CTGCGAGTGCTGTCAGAGG 
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